Catalyst Event

Sino Biopharmaceutical Ltd (1177) · Other

From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)

5/29/2026, 12:00:00 AM

OtherSentiment: Positive

The company announced positive pivotal data from two Phase III clinical trials (B-Well 1 and B-Well 2) for bepirovirsen for the treatment of chronic hepatitis B, which were presented at the 2026 European Association for the Study of the Liver (EASL) Congress and published in the New England Journal of Medicine.

Korean Translation

만성 B형 간염 치료제 베피로비르센에 대한 두 건의 3상 임상시험(B-Well 1 및 B-Well 2)의 긍정적인 주요 데이터가 2026년 유럽간학회(EASL)에서 발표되고 뉴잉글랜드 저널 오브 메디슨에 게재되었음을 발표함.

Related Recent Events

View Full Timeline